Today’s stock pick update – Open Now

Learn More How Investing In This Kind of Stock Could Change Your Life Stop wasting time looking for the right stocks. Free training on how to find perfect stock trades that can move 300-1,500% in days or weeks. (Ad) Don't be left guessing, now is the time to learn this stock picking secret. Private Payroll Growth Disappointed In February As Labor Market Recovery Remains “Sluggish”

Private payroll growth disappointed in February. ADP reported this morning that companies added just 117,000 jobs for the month, while economists had forecast a reading of 225,000. “The labor market continues to post a sluggish recovery across the board,” said Nela Richardson, chief economist at ADP. “We’re seeing large-sized companies increasingly feeling the effects of COVID-19, while job growth in the goods producing sector pauses.” Trade, transportation and util... Read More

Kopin Corporation (NASDAQ: KOPN): Kopin shares gained as much as 29% yesterday after the developer and manufacturer of high-resolution micro-displays and sub-systems posted solid fourth quarter and year-end 2020 results. “We are delighted to have finished 2020 with very strong results in both our top and bottom lines, with revenue growth of 36% year-over-year and increased effici... Read More

GILD is down -8% from an early February peak – is it a buying opportunity, or a warning sign? From that point, however, the industry has rebounded nicely, driven by progress on the vaccine front that saw approval of the third vaccine candidate over this last weekend, and increased production of the previous two already approved vaccines. That gave the industry a new sense of optimism that the end of the pandemic is in sight. It is still true that in the broadest sense, full herd immunity via vaccination isn’t likely to be reached until the middle of the year, but even as the total n... Read More

Featured Stock BioCryst Pharmaceuticals, Inc. (BCRX) – Buy Price: $13.00 or better BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase... Read More

Other Top Stories Facebook lifts ban on US political, social issue ads German officials want emails, IMs tied to real-world ID Activists sue big French retailer over Amazon forest damage Alamo Drafthouse Cinemas files for bankruptcy, seeks buyer Majority of small businesses not requiring vaccines, tests

Trend Following Picks BioCryst Pharmaceuticals, Inc. (BCRX) – Buy Price: $13.00 or better Aclaris Therapeutics, Inc. (ACRS) – Buy Price: $25.50 or better News Corporation (NWSA) – Buy Price: $25.00 or better Piedmont Lithium Limited (PLL) – Buy Price: $65.00 or better Oasis Midstream Partners LP (OMP) – Buy Price: $17.50 or better All Picks

Reversal Picks GTT Communications, Inc. (GTT) Buy Target $3.32 Sell Target $4.34 Qudian Inc. (QD) Buy Target $2.74 Sell Target $3.15 Aeglea BioTherapeutics, Inc. (AGLE) Buy Target $7.80 Sell Target $8.56 Tellurian Inc. (TELL) Buy Target $3.28 Sell Target $3.60 REGENXBIO Inc. (RGNX) Buy Target $42.27 Sell Target $45.03 All Picks

Low Price Stock Picks Vista Gold Corp. (VGZ) Isoray, Inc. (ISR) Gabriel Resources Ltd. (GBRRF) Charles & Colvard, Ltd. (CTHR) General Environmental Management, Inc. (GEVI) All Picks

Already subscribed to our premium service? Click here to Login. Not a TradersPro subscriber yet? Learn More About TradersPro Here - Learn The # 1 Key To Successful Stock Investing Profits

 

This email was sent to phanphuongthanh89.822152@blogger.com  from TradersPro by Investiv, LLC 265 N. Main | Ste. D #283 Kaysville | UT | 84037  Unsubscribe or Mange which emails you get from TradersPro Disclaimers, Terms & Conditions | Privacy Policy Copyright 2020  Investing is Inherently Risky - There are risks inherent in all investments, which may make such investments unsuitable for certain persons. These include, for example, economic, political, currency exchange, rate fluctuations, and limited availability of information on international securities. You may lose all of your money trading and investing. Do NOT enter any trade without fully understanding the worst-case scenarios of that trade. And do NOT trade with money you cannot afford to lose. Past performance of an investment is not necessarily indicative of its future results. No assurance can be given that any implied recommendation will be profitable or will not be subject to losses.